All In MedTech

FDA Clearance Tracker · P100026-S092

NeuroPace® RNS® System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 10, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 10, 2023

Approved

Time to decision

116 days

Received Oct 17, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P100026-S092
Device name
NeuroPace® RNS® System
Applicant location
Mountain View, CA
Received
Oct 17, 2022
Decided
Feb 10, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P100026

Device type

Device class
Class III

Every decision under product code PFN

FDA's approval statement

As written in FDA's record.

Approval for a revised the RNS System Implanting and Programming Program Qualifications Questionnaire as follows:1) Provided a list of current diagnostic technologies utilized to identify the seizure onset;2) Clarified that qualified neurosurgeon(s) are ABNS board-certified or board-eligible and tracking toward certification, with experience in epilepsy surgery procedures and placement of intracranial electrodes;3) Specified that an established referral relationship is needed to ensure access to neuropsychological testing and mental health services; and4) Neurologist(s) who is American Board of Psychiatry and Neurology (ABPN) board- certified and is fellowship trained in epilepsy or in clinical neurophysiology, or has experience in the treatment of epilepsy, including selection of antiepileptic medications, interpretation of scalp and intracranial EEG, video EEG monitoring, and selection of patients for epilepsy surgery or neuromodulation devices.2. Revised the RNS System Programming Physician Qualifications Questionnaire as follows:1) At least one American Board of Psychiatry and Neurology (ABPN) board-certified neurologist with expertise in epilepsy and in the interpretation of EEG;2) Established referral relationship with Epilepsy Program qualified to implant and program the RNS System;3) Local access to urgent or emergent neurosurgical care; and4) Capability to provide instructions to patient and family members in RNS System use.

Source documents

Other decisions for NeuroPace, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.